Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Calza

Showing results (131-140 of 188) with videos related to

Pageof 19
Sort By:
Infectious Diseases (London, England)|April 16, 2015
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patientsLeonardo Calza, Ilaria Danese, Vincenzo Colangeli, et al.
HIV Clinical Trials|April 20, 2017
Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatmentLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
Aging Clinical and Experimental Research|March 23, 2011
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patientNirmala Rosseti, Leonardo Calza, Benedetta Piergentili, et al.
HIV Clinical Trials|January 6, 2016
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase InhibitorsLeonardo Calza, Ilaria Danese, Eleonora Magistrelli, et al.
AIDS Research and Human Retroviruses|September 13, 2016
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral TherapyLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
The New Microbiologica|July 16, 2019
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control studyLeonardo Calza, Giulia di Pietro, Vincenzo Colangeli, et al.
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
Le Infezioni in Medicina|January 1, 2015
Raltegravir use prospectively assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profileRoberto Manfredi, Leonardo Calza, Ginevra Marinacci, et al.
Clinical and Experimental Nephrology|May 29, 2013
Prevalence of renal disease within an urban HIV-infected cohort in northern ItalyLeonardo Calza, Elisa Vanino, Eleonora Magistrelli, et al.
Infectious Diseases (London, England)|June 21, 2019
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver diseaseLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Pageof 19

Showing results (131-140 of 188) with videos related to

Sort By:
Pageof 19
Infectious Diseases (London, England)|April 16, 2015
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patientsLeonardo Calza, Ilaria Danese, Vincenzo Colangeli, et al.
HIV Clinical Trials|April 20, 2017
Prevalence of metabolic syndrome in HIV-infected patients naive to antiretroviral therapy or receiving a first-line treatmentLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
Aging Clinical and Experimental Research|March 23, 2011
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patientNirmala Rosseti, Leonardo Calza, Benedetta Piergentili, et al.
HIV Clinical Trials|January 6, 2016
Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase InhibitorsLeonardo Calza, Ilaria Danese, Eleonora Magistrelli, et al.
AIDS Research and Human Retroviruses|September 13, 2016
Significant Decrease in Plasma Levels of D-Dimer, Interleukin-8, and Interleukin-12 After a 12-Month Treatment with Rosuvastatin in HIV-Infected Patients Under Antiretroviral TherapyLeonardo Calza, Vincenzo Colangeli, Eleonora Magistrelli, et al.
The New Microbiologica|July 16, 2019
Factors associated with vitamin D deficiency in HIV-1 infected patients on combination antiretroviral therapy: a case-control studyLeonardo Calza, Giulia di Pietro, Vincenzo Colangeli, et al.
Scandinavian Journal of Infectious Diseases|September 21, 2012
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavirLeonardo Calza, Filippo Trapani, Caterina Salvadori, et al.
Le Infezioni in Medicina|January 1, 2015
Raltegravir use prospectively assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profileRoberto Manfredi, Leonardo Calza, Ginevra Marinacci, et al.
Clinical and Experimental Nephrology|May 29, 2013
Prevalence of renal disease within an urban HIV-infected cohort in northern ItalyLeonardo Calza, Elisa Vanino, Eleonora Magistrelli, et al.
Infectious Diseases (London, England)|June 21, 2019
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver diseaseLeonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Pageof 19